
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is an immuno-pharma company with potential catalysts for stock growth in the form of positive clinical data from ongoing trials, strong partnerships with major research centers for multiple cancer treatments, and an attractive current valuation with a high upside potential and enough cash to sustain the company for the next few years. Due to the long development time and potential risks, it is important for investors to consider the company's balance sheet and potential regulatory and commercialization challenges, but the positive data from recent clinical studies and regained stock listing present promising signs for future success.
Bears say
AIM ImmunoTech is an early-stage drug company that generates a high net loss, with a $4.2 million net loss in Q4 2025 and no guidance for future financials. While maintaining a BUY rating, the financial analyst has lowered their price target to $22 due to significant balance sheet/liquidity risks and potential failure of product candidates in clinical trials. These risks, along with competition, macroeconomic factors, and changing priorities in healthcare, could impact investor sentiment and the company's ability to commercialize its products and gain suitable reimbursement, making the overall outlook negative.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares